ANIP vs PAHC

For growth investors, ANI Pharmaceuticals, Inc.

(ANIP) is the stronger pick with 43. 8% revenue growth year-over-year, versus 27. 4% for Phibro Animal Health Corporation (PAHC). ANI Pharmaceuticals, Inc. (ANIP) offers the better valuation at 25. 3x trailing P/E (9. 2x forward), making it the more compelling value choice. Analysts rate ANI Pharmaceuticals, Inc. (ANIP) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ANI Pharmaceuticals, Inc.

(ANIP) is the cheapest at 25. 3x versus Phibro Animal Health Corporation at 36. 3x. On forward P/E, ANI Pharmaceuticals, Inc. is actually cheaper at 9. 2x.

Over the past 5 years, ANI Pharmaceuticals, Inc.

(ANIP) delivered a total return of +117. 4%, compared to +66. 0% for Phibro Animal Health Corporation (PAHC). Over 10 years, the gap is even starker: PAHC returned +128. 6% versus ANIP's +84. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ANI Pharmaceuticals, Inc.

(ANIP) is the lower-risk stock at 0. 63β versus Phibro Animal Health Corporation's 1. 38β — meaning PAHC is approximately 120% more volatile than ANIP relative to the S&P 500. On balance sheet safety, ANI Pharmaceuticals, Inc. (ANIP) carries a lower debt/equity ratio of 60% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ANI Pharmaceuticals, Inc.

(ANIP) is pulling ahead at 43. 8% versus 27. 4% for Phibro Animal Health Corporation (PAHC). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to 419. 2% for ANI Pharmaceuticals, Inc.. Over a 3-year CAGR, ANIP leads at 40. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ANI Pharmaceuticals, Inc.

(ANIP) is the more profitable company, earning 8. 9% net margin versus 3. 7% for Phibro Animal Health Corporation — meaning it keeps 8. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANIP leads at 12. 6% versus 8. 5% for PAHC. At the gross margin level — before operating expenses — ANIP leads at 69. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ANI Pharmaceuticals, Inc.

(ANIP) trades at 9. 2x forward P/E versus 14. 2x for Phibro Animal Health Corporation — 5. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ANIP: 47. 8% to $124. 00.

In this comparison, PAHC (1.

1% yield) pays a dividend. ANIP does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, ANI Pharmaceuticals, Inc.

(ANIP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63)). Both have compounded well over 10 years (ANIP: +84. 7%, PAHC: +128. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

PAHC pays a dividend while ANIP does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.